Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Capecitabine Chemoradiation in Locally Advanced Pancreatic Cancer
NCT01396668Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2004
- Primary completion
- Jun 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and capecitabine in pancreatic cancer (PC), sponsored by Seoul National University Hospital. Primary endpoint: Time to progression at 12 months. Started Dec 2004; status: completed.
02
Drugs
gemcitabinecisplatincapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01396668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396668.